Talc

The problem Talc addresses is real and expensive. Manual chart abstraction consumes hundreds of staff hours per study, and the people doing it are typically clinicians or trained reviewers whose time is the scarcest resource on the project. Talc's answer is to stop treating extraction as a modeling problem and start treating it as a specification problem: you write the rubric the way you'd write it for a human abstractor, and the system applies it consistently across a corpus that no human team could cover by hand. What stands out in the published material is the auditability design, not the model claims. Every extracted value carries a citation back to the source text, and ambiguous cases are flagged for human review rather than silently resolved. For pharmacovigilance and patient safety work this matters more than raw accuracy, because the reviewer has to justify each data point downstream — an extraction you can't trace is an extraction you can't use. Negation handling is the other clinically specific piece: 'no history of MI' and 'history of MI' are different facts, and generic extraction tools frequently get that wrong. The workflow claims are bounded and checkable. Set your own rules, run at scale across thousands of notes, iterate in minutes with initial results and a finished job in hours. That iteration loop is the practical differentiator against a bespoke pipeline: a BioBERT setup can be more precisely tuned, but every rubric change means an engineering cycle, whereas Talc's premise is that the rubric itself is the interface. Where we'd push back: the vendor's own site frames this as a productivity tool for teams that already know what they want to extract, and the current positioning is explicit that projects outside the medical domain aren't the target — the rubric and entity handling are clinical by design. If your need is general summarization or a non-clinical corpus, this is the wrong instrument. There's also a real prerequisite cost: if nobody on your team has an abstraction rubric written down, that work lands on you before Talc does anything. On commercial terms we have nothing solid. The pricing page wasn't reachable this run, so we can't speak to tiers, cost, contract structure, or how onboarding is sequenced. The seed notes describe a private beta with a waitlist and a Request Access gate, and the live homepage still routes every call to action through Request Access — treat any timeline you're quoted as vendor-specific rather than a published standard. The honest summary: the approach is well matched to the work, the trust features are the right ones, and the open question is purely whether a pilot on your own notes reproduces the accuracy the workflow implies.